The Standard

The Official Blog of Health Level Seven® International

visit HL7.org 

Dr. Patrick Jolomba

Dr. Patrick Jolomba
Dr. Patrick Jolomba, PhD, is the Founder and Director of BioSEC Digital Innovation. He is a healthcare scientist, medical affairs leader and digital health innovator whose work sits at the intersection of immersive technology, artificial intelligence and clinical education. His PhD evaluated virtual reality for peritoneal dialysis catheter insertion training, and the question it raised has shaped his work since: not whether immersive technology is impressive, but whether it demonstrably changes what clinicians can do, and how we prove it. That distinction matters most where resources are tightest. Patrick argues that immersive tools designed for well-funded simulation centres rarely survive contact with intermittent bandwidth, shared headsets, multilingual cohorts and thin technical support — and that the answer is not to lower expectations for low- and middle-income settings, but to design, adapt and evaluate for them from the outset. He previously served five years on a UK Health Research Authority Research Ethics Committee and holds a Visiting Lectureship at the University of Northampton.

Recent Posts

From NCD Risk to National Health-System Foresight: Building B-HIP with HL7 FHIR

[fa icon="calendar'] Nov 9, 2026, 4:31:09 PM / by Dr. Patrick Jolomba posted in FHIR, HL7, HL7 community, interoperability, health IT, clinical decision support, AI, AI Challenge, population health, B-HIP

[fa icon="comment"] 0 Comments


Winner of the Most Innovative Award for HL7’s 2026 AI Challenge

Non-communicable diseases (NCDs) are no longer only a clinical challenge. They are a health-system, economic, and development challenge.

NCDs account for 75% of non-pandemic-related deaths worldwide. Cardiovascular disease, cancer, chronic respiratory disease and diabetes cause 80% of all premature NCD deaths, and 73% of NCD deaths occur in low- and middle-income countries. [1,4]

Botswana shows why the next phase of NCD prevention must combine clinical care with better data use. The latest national STEPS ( STEPwise approach to NCD risk factor surveillance) survey found that hypertension prevalence rose from 31.1% in 2014 to 39.6% in 2024. Nearly half of adults are now overweight, and more than one in five are obese. [2]

These diseases do not occur independently. Hypertension, diabetes, obesity, cardiovascular disease and chronic kidney disease (CKD) share risk factors, biological pathways and, ultimately, the same patient. Yet our digital systems often still manage them in separate clinical and administrative silos.

That fragmentation is one of the problems we set out to address with the BioESC Health Intelligence Platform (B-HIP). B-HIP received the Most Innovative Award in the 2026 HL7 International AI Challenge, selected from 73 submissions across 25 countries. It was the category's first year and the first time an African-led platform has received the award.

The Idea: Detect Earlier, Connect the Data, Act Sooner

B-HIP began with a simple question. What if the same interoperable data used to estimate one patient's future risk could also help a health system understand its future clinical and economic burden?

The answer is an architecture designed around prevention rather than late-stage disease management. B-HIP brings together a patient-facing mobile app, a clinician portal, a FHIR-based longitudinal health record, disease registries, clinical decision support, e-referral pathways, and population-health analytics.

Rather than building separate digital tools for hypertension, diabetes, kidney disease and cardiovascular risk, we aim to create one common health-intelligence layer in which these conditions are understood together.

One Person, Multiple Risks: The Patient Twin

We call the individual-level view the Patient Twin. It brings together observations such as blood pressure, weight, glucose, kidney function, medications, diagnoses, and laboratory results to build a longitudinal picture of each person’s NCD risk.

Validated clinical models then sit within that common architecture. For kidney disease, B-HIP uses established measures such as the CKD-EPI equation and the Kidney Failure Risk Equation (KFRE), which has been externally validated across international populations. [3] The same architecture can progressively add cardiovascular risk, hypertension control, diabetes risk, and other validated models, without building a new digital system for each disease.

This distinction matters. B-HIP does not rely on a single artificial-intelligence algorithm that claims to predict everything. It is a standards-based environment in which validated clinical equations, machine-learning tools and decision-support pathways coexist, with full transparency about where each prediction comes from.

Read More [fa icon="long-arrow-right"]

Lists by Topic

see all

Posts by Topic

see all